| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. | SVP, Chief Financial Officer | Common Stock | 145K | $534K | $3.68 | Jul 28, 2022 | Direct |
| AGILE THERAPEUTICS INC | Chief Financial Officer | Common Stock | 0 | $0 | $1.52 | Aug 26, 2024 | Direct |
| Aprea Therapeutics, Inc. | SVP, Chief Financial Officer | Stock Option (right to Buy) | 89.2K | Jul 28, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AGRX | AGILE THERAPEUTICS INC | Aug 26, 2024 | 2 | -$30.5K | 4 | Aug 26, 2024 | Chief Financial Officer |
| AGRX | AGILE THERAPEUTICS INC | Oct 3, 2023 | 1 | $0 | 4 | Oct 4, 2023 | Chief Financial Officer |
| AGRX | AGILE THERAPEUTICS INC | Aug 16, 2023 | 0 | $0 | 3 | Aug 25, 2023 | Chief Financial Officer |
| APRE | Aprea Therapeutics, Inc. | Jul 28, 2022 | 2 | $0 | 4 | Aug 1, 2022 | SVP, Chief Financial Officer |
| APRE | Aprea Therapeutics, Inc. | Jun 3, 2022 | 1 | -$28.4K | 4 | Jun 7, 2022 | SVP, Chief Financial Officer, Director |
| APRE | Aprea Therapeutics, Inc. | Mar 10, 2022 | 2 | $0 | 4 | Mar 14, 2022 | SVP, Chief Financial Officer, Director |
| APRE | Aprea Therapeutics, Inc. | Feb 25, 2022 | 1 | -$25.8K | 4 | Mar 1, 2022 | SVP, Chief Financial Officer |
| APRE | Aprea Therapeutics, Inc. | Aug 25, 2021 | 1 | -$30K | 4 | Aug 27, 2021 | SVP, Chief Financial Officer |